Advertisement

U.S. inks coronavirus trial vaccine deal with Pfizer for first 100M doses

Click to play video: 'Coronavirus: Vaccine trials showing positive immune responses'
Coronavirus: Vaccine trials showing positive immune responses
Early results of two vaccine trials out of the United Kingdom and China are providing hope in the search for a COVID-19 cure. As Redmond Shannon reports, the Oxford and CanSino human clinical trials have have recorded positive immune system responses – Jul 20, 2020

The U.S. has signed a contract with Pfizer for delivery in December of the first 100 million doses of a coronavirus vaccine the pharmaceutical company is working to develop, says a top American official.

Health and Human Services Secretary Alex Azar made the announcement on Wednesday and added that the U.S. could also could buy another 500 million doses under the agreement.

“Now those would, of course, have to be safe and effective” and be approved by the Food and Drug Administration, Azar said during an appearance on Fox News.

READ MORE: Pfizer prepares for large-scale vaccine production

Pfizer Inc. and BioNTech SE announced separately that the agreement is with HHS and the Defence Department for a vaccine candidate the companies are developing jointly.

The agreement is part of President Donald Trump’s Operation Warp Speed vaccine program, under which multiple COVID-19 vaccines are being developed simultaneously.

Story continues below advertisement

The program aims to deliver 300 million doses of a safe and effective COVID-19 vaccine by January 2021, according to HHS.

READ MORE: A look at what could happen without a coronavirus vaccine

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

Under the initiative, the government will speed development and buy vaccines — before they are deemed safe and effective — so that the medication can be in hand and quickly distributed once the FDA approves or authorizes its emergency use.

Pfizer and BioNTech said the U.S. will pay $1.95 billion upon receipt of the first 100 million doses, following FDA authorization or approval.

Azar said the contract with Pfizer and BioNTech brings to five the number of potential coronavirus vaccines that are under development.

Click to play video: 'Poll: Most Canadians support mandatory masks, vaccines'
Poll: Most Canadians support mandatory masks, vaccines

Trump said Tuesday at a briefing that “the vaccines are coming, and they’re coming a lot sooner than anyone thought possible, by years.”

Story continues below advertisement

But other countries are also scrambling to get their hands on a vaccine for COVID-19, which has killed more than 617,000 people, according to a tally kept by Johns Hopkins University.

Nearly 4 million Americans have been infected by the new coronavirus and at least 142,000 have died from COVID-19, the disease it causes, according to Johns Hopkins.

Britain announced Monday it had secured access to another 90 million experimental COVID-19 vaccines made by Pfizer and others, a move some campaigners warned could worsen a global scramble by rich countries to hoard the world’s limited supply of COVID-19 vaccines.

Nearly two dozen potential vaccines are in various stages of human testing worldwide, with a handful entering necessary late-stage testing to prove effectiveness.

Click to play video: 'Coronavirus: WHO says global supply of COVID-19 vaccine will be future challenge'
Coronavirus: WHO says global supply of COVID-19 vaccine will be future challenge

Sponsored content

AdChoices